Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright

Immix Biopharma, Inc. (NASDAQ:IMMX) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for Immix Biopharma in a report issued on Monday, August 10th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.17) per share for the quarter, down from their previous forecast of ($0.14). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Immix Biopharma’s Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.72) EPS, Q1 2027 earnings at ($0.23) EPS, Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.01) EPS and Q4 2027 earnings at $0.31 EPS.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Friday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01).

A number of other analysts have also issued reports on the stock. Citigroup initiated coverage on shares of Immix Biopharma in a research note on Thursday, June 18th. They set a “buy” rating on the stock. Needham & Company LLC assumed coverage on shares of Immix Biopharma in a research note on Wednesday, July 22nd. They issued a “buy” rating and a $21.00 target price for the company. Lifesci Capital started coverage on shares of Immix Biopharma in a report on Wednesday, June 17th. They set an “outperform” rating and a $19.00 price target for the company. Bank of America initiated coverage on shares of Immix Biopharma in a research note on Thursday, June 18th. They set a “buy” rating and a $27.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a report on Friday, July 17th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $21.29.

Immix Biopharma Stock Performance

Immix Biopharma stock opened at $11.49 on Wednesday. The firm has a market capitalization of $625.17 million, a PE ratio of -13.06 and a beta of 0.11. Immix Biopharma has a one year low of $1.94 and a one year high of $12.14. The stock’s 50 day moving average price is $9.46 and its 200 day moving average price is $8.94.

Hedge Funds Weigh In On Immix Biopharma

A number of institutional investors have recently made changes to their positions in the business. Allworth Financial LP acquired a new stake in shares of Immix Biopharma during the fourth quarter worth approximately $30,000. Everhart Financial Group Inc. acquired a new stake in Immix Biopharma in the second quarter valued at $103,000. Mathes Company Inc. acquired a new stake in Immix Biopharma in the fourth quarter valued at $56,000. Balyasny Asset Management L.P. bought a new position in Immix Biopharma during the 4th quarter valued at $67,000. Finally, Kera Capital Partners Inc. bought a new position in Immix Biopharma during the 4th quarter valued at $68,000. 11.26% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Immix Biopharma

Here are the key news stories impacting Immix Biopharma this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $25.00 price target, implying substantial upside from recent trading levels. The analyst expects Immix Biopharma to reach positive earnings of $0.31 per share in the fourth quarter of 2027, suggesting a potential longer-term path toward profitability.
• Positive Sentiment: A separate report cited a consensus analyst target price of $20.71, which is also above the company’s recent share price. Immix Biopharma, Inc. Receives $20.71 Consensus Target Price from Analysts
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day short-interest ratio. Because the data appears inconsistent—including a reported “NaN” percentage change—it provides little reliable insight into current trading pressure.
• Negative Sentiment: HC Wainwright reduced its estimates for third-quarter 2026 EPS to a loss of $0.17 from a loss of $0.14, fourth-quarter 2026 EPS to a loss of $0.19 from a loss of $0.15, and full-year 2026 EPS to a loss of $0.72 from a loss of $0.62. The revisions indicate weaker expected results and continued losses in the near term.
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Immix Biopharma investors. The notice does not establish wrongdoing, but news of a potential securities-related investigation can weigh on investor sentiment and increase legal uncertainty. Pomerantz Law Firm Investor Alert

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.